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In 2001, Myanmar (Burma) had its largest outbreak of
dengue—15,361 reported cases of dengue hemorrhagic
fever/dengue shock syndrome (DHF/DSS), including 192
deaths. That year, 95% of dengue viruses isolated from
patients were serotype 1 viruses belonging to two lineages
that had diverged from an earlier, now extinct, lineage
sometime before 1998. The ratio of DHF to DSS cases in
2001 was not significantly different from that in 2000, when
1,816 cases of DHF/DSS were reported and dengue 1 also
was the most frequently isolated serotype. However, the
2001 ratio was significantly higher than that in 1998 (also
an outbreak year) and in 1999, when all four serotypes
were detected and serotypes 1, 2, and 3 were recovered in
similar numbers. The large number of clinical cases in 2001
may have been due, in part, to a preponderance of infec-
tions with dengue 1 viruses. 
D
engue is a disease caused by four serotypes of a fla-
vivirus of the same name (1). Infection with these
viruses may be inapparent, or it may result in disease vary-
ing in severity from a mild influenza-like illness to hemor-
rhagic fever and hypovolemic shock, which may be fatal if
untreated (1). Dengue is an important source of illness and
death in tropical nations, particularly in Southeast Asia and
Central and South America (2). In 1998, a pandemic of
dengue resulted in 1.2 million cases of dengue hemorrhag-
ic fever (DHF) in 56 countries (3). In many countries in
Asia where this disease is endemic, outbreaks occur in
cycles of 3 to 5 years due, perhaps, to enhanced infection
with one serotype caused by cross-reactive antibody pro-
duced in response to an earlier infection with a second
serotype (4), rather than to climatic effects (5).
Furthermore, the incidence of disease and its severity vary
between primary and secondary infections and between
infections with different dengue virus serotypes (6–8). All
four dengue virus serotypes circulate in countries in
Southeast Asia from Myanmar to Indonesia (9–13), and no
outbreaks caused by single virus serotypes, as have been
seen in dengue non-endemic areas such as Cuba or
Australia (14,15), have recently been reported.
Phylogenetic studies have shown regular extinction of
strains of dengue viruses in single locations and emergence
of new strains (16,17), and it has been suggested that the
appearance of more fit or more pathogenic viruses may
occur as a result of immunologic selection during periods
of intense transmission during outbreaks (18). While weak
selective pressure on the envelope (E) protein gene of
some dengue viruses is evident (19), the most extensive
changes in virus genotypes appear to be due to recombina-
tion or to possible genetic bottlenecks (16,17,20). Given
these observations, and the finite pool of hosts in most
locations (humans and selected species of Aedes mosqui-
toes), perhaps it is surprising that greater competition
between the four serologically related serotypes of dengue
virus has not been observed, e.g., the complete exclusion
of two or three serotypes from an ecologic niche. 
Patients and Methods
Serology
Acute- and, when possible, convalescent-phase serum
samples were obtained from patients admitted to the
Yangon Children’s Hospital with a clinical diagnosis of
DHF (1). A patient with a confirmed case of dengue fever
was one who met any of the following criteria: 1) paired
sera showed a fourfold or greater rise in hemagglutination
inhibiting (HI) antibody titer against dengue virus (21); 2)
a convalescent-phase serum sample produced an
immunoglobulin (Ig) G reaction (titer equivalent to an
anti-dengue virus HI titer of >2,560), an IgM reaction in a
commercial “rapid” dengue test (22), or both; or 3) dengue
Myanmar Dengue Outbreak
Associated with Displacement of
Serotypes 2, 3, and 4 by Dengue 1 
Hlaing Myat Thu,*† Kym Lowry,* Thein Thein Myint,‡ Than Nu Shwe,‡ Aye Maung Han,‡ 
Kyu Kyu Khin,§ Kyaw Zin Thant,† Soe Thein,† and John Aaskov*
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 4, April 2004 593
*Queensland University of Technology, Brisbane, Australia;
†Department of Medical Research, Yangon, Myanmar; ‡Yangon
Children’s Hospital, Yangon, Myanmar; and §Mawlamyaing
General Hospital, Mawlamyaing, Myanmar virus was recovered by culturing 140 µL of acute-phase
serum on 25-cm2 monolayers of C6–36 A. albopictus cells
for 7 days. The serotype of the virus was determined by
performing indirect immunofluorescence (23) on cells
from the cultures of C6–36 cells used for virus isolation
with flavivirus-, dengue-, or serotype-specific monoclonal
antibodies (23,24).
Phylogenetic Analyses
RNA was extracted from virus isolates with a commer-
cial kit (Qiagen, Hilden, Germany) according to the man-
ufacturer’s instructions, transcribed to cDNA, and
amplified by polymerase chain reaction as described previ-
ously (24). The cDNAwas purified and then sequenced on
an automated sequencer (Applied Biosystems, Inc., Foster
City, CA) (24). Nucleotide sequences were edited, com-
pared, and analyzed with software (EclustalW, Ednapars,
Ednadist, Ekitsch) from the Australian Genome
Information Service (available from: http://www.angis.
org.au). Additional nucleotide sequences used in the phy-
logenetic analyses are listed as country, year of isolation,
dengue virus serotype, and GenBank accession number,
i.e., (Sin[gapore]90D1, M87512; Abid[jan]99D1,
AF298807; Mal[aysia]72D1-12, AF231721; Thai64D1,
AF180817; Thai58D1, D10513; Phil[ippines]D1, D00503;
Nauru74 D1, U88535; Mex[ico]83D1, D00504;
Jam[aica]77D1, D00501; Japan43D1M, AB074760;
Haw[aii]44D1, X76219; Lao96D1, AB003090; China
80D1, AF350498; Camb[odia]98D1, AF309641).
Results
Dengue is endemic in Myanmar. Outbreaks have
occurred in 3- to 5-year cycles of increasing magnitude
since the first recorded outbreak in the country in 1970
(Table 1). The outbreak in 2001 (15,361 cases of
DHF/dengue shock syndrome [DSS]) was the largest on
record. 
In 1998 and 1999, all four dengue virus serotypes
(DENV-1–4) were recovered from patients in the Yangon
Children’s Hospital; DENV-1, -2, and -3 were recovered in
approximately similar ratios each year (Table 2). In 2000
and 2001, no DENV-4 was recovered, and DENV-1 was
recovered more frequently than any other serotype. In
2001, 95% of isolates were DENV-1. No significant differ-
ence (p > 0.05, chi-square test) was found in the rate of iso-
lation of dengue viruses from seronegative serum samples
for each of these years.
Accompanying the change in the relative proportions of
dengue virus serotypes recovered from patients in the
Yangon Children’s Hospital was a significant change in the
relative proportion of clinically diagnosed DHF and DSS
cases (1998: 3,194 DHF, 1,402 DSS; 1999: 1,741 DHF
601, DSS; 2000: 896 DHF, 224 DSS; 2001: 4,511 DHF,
1,105 DSS), i.e., DSS occurred in a smaller proportion of
patients in 2000 and 2001 than in 1999 or 1998 (p < 0.01,
chi-square test). Hemorrhagic signs and symptoms devel-
oped in most of the dengue fever patients in 2001; such
patients were distinguished from DHF patients only on the
basis that their platelet levels were >100,000/mm3.
Of the patients with a laboratory-confirmed dengue
infection and sufficient clinical and laboratory detail to
confirm the grade of infection (990 patients), almost half
(455) had a primary infection. However, DSS was more
prevalent in patients with secondary infections (112/535)
than in those with a primary infection (43/455). The medi-
an age of patients with primary infections (5 years) was not
significantly different (p < 0.05, Wilcoxon rank sum) from
those with a secondary infection (6 years). Thirty-nine of
the primary infections occurred in children <1 year of age;
shock developed in 7 of these children. Of the remainder,
17 had DF, 12 had DHF grade I, and 3 had DHF grade II).
Virus (dengue 1) was recovered from the acute-phase
serum of three of these seven DSS patients. Two patients
<1 year of age had a secondary infection; dengue fever
developed in both.
Phylogenetic analyses of the nucleotide sequences of
the E protein gene of the only pre-1998 DENV-1 available
from Myanmar along with 3 of the 9 isolates from 1998,
both 1999 isolates, 5 of the 6 isolates from 2000, and 8 of
the 115 isolates from 2001 (including an isolate recovered
from a single female A. aegypti mosquito [My01D1m193]
collected in the home of a dengue patient
[My01D141500]) suggested that two new strains of
DENV-1 had appeared some time before 1998, i.e., all
three clades of Myanmar DENV-1 viruses have 1998
viruses in them (Figure 1). The clade containing the 1996
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Table 1. Annual dengue hemorrhagic fever cases, Myanmar 
Y  Cases  Y  Cases  Y  Cases  Y  Cases 
1970  1,654  1978  2,029  1986  2,114  1994  11,647 
1971  691  1979  4,685  1987  7,331  1995  2,218 
1972  1,013  1980  2,026  1988  1,178  1996  1,854 
1973  349  1981  1,524  1989  1,196  1997  4,006 
1974  2,477  1982  1,706  1990  6,318  1998  12,918 
1975  6,750  1983  2,756  1991  6,770  1999  5,753 
1976  3,153  1984  2,273  1992  1,685  2000  1,816 
1977  5,364  1985  2,666  1993  1,979  2001  15,361 isolate (My96D123819) may be extinct (no examples have
been identified since 1998). There was no apparent segre-
gation of the viruses in the two most recent clades of
Myanmar viruses according to the township (suburb)
where the patient lived or to the date of onset of symptoms,
i.e., viruses from both clades appeared to be co-circulating.
There were 210 nucleotide differences between the
sequences of the E protein genes of the My96D123819 and
My98D132514 viruses and those of the remaining
Myanmar viruses. Forty-six of these resulted in amino acid
changes. Amino acid changes at E37 (N-D), E155 (T-S),
E161 (I-T), E329 (A-T), E369 (T-E), E442 (A-T), E468 (I-
N) and E492 (T-V) distinguished these two viruses from
all other Myanmar DENV-1. 
The nucleotide sequences of the E genes of the viruses
recovered from a patient and a female A. aegypti mosqui-
to from the same house varied at three sites. Two of the
changes were silent, and the third resulted in a nonconser-
vative amino acid change at E261 from R (in the patient)
to H (in the mosquito). Virus from one other patient
(My00D136957) had R at this position, but virus from all
other patients had the same amino acid as the mosquito at
this site.
Discussion
The dengue outbreak in Myanamar in 2001 occurred at
a time not unanticipated from the usual 3- to 4-year cycles
of outbreaks in that country (Table 1). Nevertheless, we are
unaware of any previous examples of dengue outbreaks, in
countries in which all four dengue virus serotypes are cir-
culating, in which a single serotype has risen to the promi-
nence that DENV-1 appears to have reached in Myanmar
in 2001. 
The number of dengue cases in Yangon from 1998 to
2001 was not obviously correlated with the temperature or
rainfall (Figure 2) other than the fact that the average tem-
perature in April of the 2 epidemic years (1988, 38.5°C;
2001, 39.1°C) was almost 2°C higher than the highest aver-
age in the nonepidemic years. These observations are in
broad agreement with those made in Bangkok over much
larger periods (4,5) that weather was not a major factor in
determining when dengue outbreaks occurred. However,
associations between meterologic conditions and dengue
outbreaks could be missed if comparisons are made
between aggregated monthly totals (rainfall) or monthly
averages (temperature) rather than with daily values. 
Why or how the change in the composition of dengue
virus populations circulating in Yangon occurred is not
clear. If the DENV-1 populations diversified in the
1994–1998 interepidemic period, the changes could have
been due to a genetic bottleneck, such as has been pro-
posed to explain the disappearance of ancestral strains and
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Table 2. Dengue virus (DENV) serotypes recovered from patients in Yangon Children’s Hospital, 1998–2001  
  1998  1999  2000  2001 
Clinical cases  4,596  2,342  1,100  5,616 
Paired sera  709  739  501  1870 
Confirmed cases  496  373  274  1,481 
Sera with HI titer <80 for virus isolation  54  30  42  236 
DENV-1 isolates  9  2  6  115 
DENV-2 isolates  5  5  1  1 
DENV-3 isolates  9  3  1  3 
DENV-4 isolates  1  1  0  0 
Mixed virus isolates  0  0  0  2 (dengue 1+2) 
aHI, hemagluttination inhibition 
Figure 1. Phylogenetic analysis of the nucleotide sequences of the
E protein genes of dengue 1 viruses from Myanmar and of dengue
1 viruses from other localities.the appearance of new strains of DENV-2 and -3 in
Thailand (16,17). Strong immunologic pressures on
dengue virus populations during rapid transmission in out-
breaks could give rise to serologic-escape mutant popula-
tions of virus (18). In the 1998 dengue outbreak in Yangon,
in which DENV-1–4 were recovered from patients, all
DENV-1 analyzed in this study were recovered in August
and September, just after the season had peaked (June 835
DHF/DSS cases; July 845 DHF/DSS cases; August 829
DHF/DSS cases; September, 516 DHF/DSS cases). Six of
the eight amino acid changes (see above) that distin-
guished the two post-1998 DENV-1 lineages from the ear-
lier one occurred in the portion of the E protein above the
lipid membrane of the virion (E468 and E492 are in the
putative transmembrane anchor region of the E protein
[25]). The amino acids at E 155 of the pre-1998 lineage of
DENV-1 and all 1998 strains of DENV-2–4 were the same
(T) and differed from that at this position in the post-1998
DENV-1 lineages (S). At E37 and 442, the pre-1998 line-
age DENV-1 isolates shared the same amino acid as 1998
lineages of DENV-2 and -3 and of DENV-2, respectively,
and these differed from the amino acids in the correspon-
ding positions of the post-1998 DENV-1 lineages (Table
3). These changes might be taken as evidence of selective
pressure imposed on DENV-1 by cross-reactive antibodies
produced against the co-circulating DENV-2, -3, or -4.
Despite these observations, others have been unable to find
any evidence of selection acting on the E protein of
DENV-1 in nature (19). Furthermore, gaps in the regional
virologic record make it difficult to determine whether the
post-1998 strains of DENV-1 in Myanmar were introduced
or whether they evolved locally.
One further difference between the observations of the
dengue outbreaks in Yangon from 1984 to 1988 (7) and in
2001 was the proportion of dengue patients who had pri-
mary infections. From 1984 to 1988, 15% of patients
admitted to the Yangon Children’s Hospital had a primary
infection (7). In 2001, 455 (46%) of 990 virologically or
serologically confirmed dengue patients had a primary
infection. This increase in the proportion of patients with
primary infections may have contributed to the decrease in
the proportion of DSS cases (6,7). Other researchers (8)
have observed that primary infections with DENV-1 and -
3 result in clinical disease more frequently than primary
infections with DENV-2 or -4. The data from Myanmar in
2001 are compatible with these observations if the rate of
isolation of each dengue virus serotype from patients in
Myanmar in 2001 reflected the infection rate with each
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Figure 2. Relationship between weather conditions and the num-
ber of cases of dengue in Yangon, 1998–2001. (a) Comparison of
the monthly admissions of dengue (dengue fever, dengue hemor-
rhagic fever, and dengue shock syndrome) patients to the Yangon
Children’s Hospital with the total monthly rainfall. (b) The average
monthly maximum and minimum temperatures in Yangon from
1997 to 2001 and the difference between these values. 
Table 3. Comparison of amino acid changes in dengue 1 virus (DENV-1) E proteins with the sequence of the same region of co-
circulating strains of DENV 2–4
a 
Y  Position  Amino acid sequence 
    DENV-1  DENV-2  DENV-3  DENV-4 
1998  E37  MAKNKPT  MAKNKPT  MAKNKPT  MAQGKPT 
Post-1998    MAKDKPT       
1998  E155  GNETTEH  GNDTGKH  GNDTQGH  GNDTSNH 
Post-1998    GNESTEH       
1998  E369  IEATPPF  IEAEPPF  IEAEPPF  IELEPPF 
Post-1998    IEAEPPF       
1998  E442  IFGAAYG  VFGAIYG  DFGSVGG  VFGSVYT 
Post-1998    IFGTAYG       
aAmino acids in bold occur at the positions in the E protein indicated, e.g., E37, E155. type in the community at large. The observation of a lower
incidence of DSS among patients in 2001, when most
infections may have been due to DENV-1, than from 1984
to 1988 (7) or in 1998 and 1999 agrees with previous
observations that DSS occurs most commonly after infec-
tions with DENV-2 in hosts who have had a prior infection
with another dengue serotype (6,7). This report provides
further evidence of the ability of dengue viruses to under-
go rapid and unpredictable changes in genotype (16,17)
and of the association of such changes with major changes
in disease incidence and severity.
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